{"id":23152,"date":"2024-03-18T09:45:39","date_gmt":"2024-03-18T08:45:39","guid":{"rendered":"https:\/\/ggba.swiss\/?p=23152"},"modified":"2024-03-18T09:45:42","modified_gmt":"2024-03-18T08:45:42","slug":"alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/","title":{"rendered":"Alithea Genomics embarks on next-phase growth with CHF 2.8 million funding"},"content":{"rendered":"\n<p><a href=\"https:\/\/alitheagenomics.com\/\">Alithea Genomics<\/a>, renowned for its trailblazing Bulk RNA Barcoding and sequencing (BRB-seq) technology, sets its sights on a series of ambitious endeavors including the launch of new RNA sequencing products, amplification of production capacity, development of pioneering technologies, and the establishment of a United States subsidiary.<\/p>\n\n\n\n<p>The company\u2019s BRB-seq technology represents a paradigm shift in RNA sequencing, offering an ultra-high throughput and cost-effective alternative to traditional methods. This innovative approach simplifies the sample preparation process, enabling the processing of hundreds of RNA samples simultaneously, thereby accelerating research and drug discovery ventures.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">New headquarters in the heart of the Health Valley<\/h4>\n\n\n\n<p>Spearheaded by <a href=\"https:\/\/noval.is\/\">Novalis Biotech<\/a> and joined by new investor <a href=\"https:\/\/techuventures.com\/\">TechU Ventures<\/a>, alongside existing stakeholders, the new funding in the amount of CHF 2.8 million will catalyze Alithea\u2019s commercial trajectory, with plans to broaden the reach of its groundbreaking BRB-seq and DRUG-seq technologies. DRUG-seq, an addition to Alithea\u2019s portfolio, eliminates the need for RNA isolation, offering a streamlined path for drug development processes, and has already garnered attention from major pharmaceutical entities.<\/p>\n\n\n\n<p>With the establishment of a subsidiary in the United States, Alithea aims to tap into the lucrative American market, fostering international collaborations and extending its innovative solutions to a wider audience. Furthermore, the move to new headquarters in Lausanne, equipped with state-of-the-art laboratories, reinforces Alithea&#8217;s commitment to advancing RNA sequencing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lausanne-based Alithea Genomics has announced the successful closing of a CHF 2.8 million extension of its seed financing, a significant step towards revolutionizing RNA sequencing technologies.<\/p>\n","protected":false},"author":6,"featured_media":23153,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,908,894,902,885],"class_list":["post-23152","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-diagnostic","tag-financing","tag-personalized-medicine","tag-vaccines"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alithea embarks on next-phase growth with CHF 2.8 million funding<\/title>\n<meta name=\"description\" content=\"Lausanne-based biotech Alithea Genomics has announced the successful closing of a CHF 2.8 million financing round.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alithea embarks on next-phase growth with CHF 2.8 million funding\" \/>\n<meta property=\"og:description\" content=\"Lausanne-based biotech Alithea Genomics has announced the successful closing of a CHF 2.8 million financing round.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-18T08:45:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-18T08:45:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Alithea-Genomics-BRB-seq-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Alithea Genomics embarks on next-phase growth with CHF 2.8 million funding\",\"datePublished\":\"2024-03-18T08:45:39+00:00\",\"dateModified\":\"2024-03-18T08:45:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/\"},\"wordCount\":234,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Alithea-Genomics-BRB-seq-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Diagnostic\",\"Financing\",\"Personalized Medicine\",\"Vaccines\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/\",\"url\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/\",\"name\":\"Alithea embarks on next-phase growth with CHF 2.8 million funding\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Alithea-Genomics-BRB-seq-1180x811-1.jpeg\",\"datePublished\":\"2024-03-18T08:45:39+00:00\",\"dateModified\":\"2024-03-18T08:45:42+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Lausanne-based biotech Alithea Genomics has announced the successful closing of a CHF 2.8 million financing round.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Alithea-Genomics-BRB-seq-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Alithea-Genomics-BRB-seq-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Alithea Genomics, which emerged from the EPFL in 2020, has distinguished itself within the life sciences sector with its cutting-edge RNA sequencing solutions. | \u00a9 Alithea Genomics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alithea Genomics embarks on next-phase growth with CHF 2.8 million funding\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alithea embarks on next-phase growth with CHF 2.8 million funding","description":"Lausanne-based biotech Alithea Genomics has announced the successful closing of a CHF 2.8 million financing round.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/","og_locale":"en_US","og_type":"article","og_title":"Alithea embarks on next-phase growth with CHF 2.8 million funding","og_description":"Lausanne-based biotech Alithea Genomics has announced the successful closing of a CHF 2.8 million financing round.","og_url":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-03-18T08:45:39+00:00","article_modified_time":"2024-03-18T08:45:42+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Alithea-Genomics-BRB-seq-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Alithea Genomics embarks on next-phase growth with CHF 2.8 million funding","datePublished":"2024-03-18T08:45:39+00:00","dateModified":"2024-03-18T08:45:42+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/"},"wordCount":234,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Alithea-Genomics-BRB-seq-1180x811-1.jpeg","keywords":["Biotech","Diagnostic","Financing","Personalized Medicine","Vaccines"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/","url":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/","name":"Alithea embarks on next-phase growth with CHF 2.8 million funding","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Alithea-Genomics-BRB-seq-1180x811-1.jpeg","datePublished":"2024-03-18T08:45:39+00:00","dateModified":"2024-03-18T08:45:42+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Lausanne-based biotech Alithea Genomics has announced the successful closing of a CHF 2.8 million financing round.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Alithea-Genomics-BRB-seq-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/03\/Alithea-Genomics-BRB-seq-1180x811-1.jpeg","width":1180,"height":811,"caption":"Alithea Genomics, which emerged from the EPFL in 2020, has distinguished itself within the life sciences sector with its cutting-edge RNA sequencing solutions. | \u00a9 Alithea Genomics"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/alithea-genomics-embarks-on-next-phase-growth-with-chf-2-8-million-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Alithea Genomics embarks on next-phase growth with CHF 2.8 million funding"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/23152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=23152"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/23152\/revisions"}],"predecessor-version":[{"id":23156,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/23152\/revisions\/23156"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/23153"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=23152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=23152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=23152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}